

SEQUENCE LISTING

<110> IZUMU SAITO

<110> SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

<120> DNA comprising mutant FRT sequence

<130> 00-053-PCT

<150> JP 11-280210

<151> 1999-9-30

<150> JP 11-346727

<151> 1999-12-6

<160> 36

<210> 1

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 1

gaagttccta tactttctag agaataggaa cttc

34

<210> 2

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 2

gaagttccta tactctctgg agaataggaa cttc

34

<210> 3

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 3

gaagttccta tactctccag agaataggaa cttc

34

<210> 4

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 4

gaagttccta tactatcttg agaataggaa cttc

34

<210> 5

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 5

gaagttccta tactttctgg agaataggaa cttc

34

<210> 6

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 6

gaagttccta tactatttga agaataggaa cttc

34

<210> 7

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 7

gaagttccta taccttgtga agaataggaa cttc

34

<210> 8

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 8

gaagttccta tactatctac agaataggaa cttc

34

<210> 9

<211> 34

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 9

gaagttccta tactgtctat agaataggaa cttc

34

<210> 10

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> The oligonucleotide is synthesized DNA adaptor.

<400> 10

agcttctgca gcagaccgtg catcatg

27

<210> 11

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> The oligonucleotide is synthesized DNA adaptor.

<400> 11

atgcacggtc tgctgcaga

19

<210> 12

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on wild type FRT sequence.

<400> 12

tcgaggacgt cgaagttcct atactttcta gagaatagga acttctccgg aa

52

<210> 13

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on wild type FRT sequence.

<400> 13

ctagttccgg agaagttcct atttctctaga aagtatagga acttcgacgt cc

52

<210> 14

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 14

tcgaggacgt cgaagttcct atactatcta gagaatagga acttctccgg aa

52

<210> 15

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 15

tcgaggacgt cgaagttcct atactttctg gagaatagga acttctccgg aa

52

<210> 16

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 16

tcgaggacgt cgaagttcct atactttcta cagaatagga acttctccgg aa

52

<210> 17

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 17

tcgaggacgt cgaagttcct atactatttg aagaatagga acttctccgg aa

52

<210> 18

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 18

tcgaggacgt cgaagttcct atactctctg gagaatagga acttctccgg aa

52

<210> 19

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 19

tcgaggacgt cgaagttcct atactatcta cagaatagga acttctccgg aa

52

<210> 20

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 20

tcgaggacgt cgaagttcct atactctcca gagaatagga acttctccgg aa

52

<210> 21

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 21

tcgaggacgt cgaagttcct atactatctt gagaatagga acttctccgg aa

52

<210> 22

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 22

tcgaggacgt cgaagttcct atactgtcta tagaatagga acttctccgg aa

52

<210> 23

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 23

ctagttccgg agaagttcct attctctaga tagtatagga acttcgacgt cc 52

<210> 24

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 24

ctagttccgg agaagttcct attctccaga aagtatagga acttcgacgt cc 52

<210> 25

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 25

ctagttccgg agaagttcct attctgtaga aagtatagga acttcgacgt cc 52

<210> 26

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 26

ctagttccgg agaagttcct attcttcaaa tagtatagga acttcgacgt cc 52

<210> 27

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 27

ctagttccgg agaagttcct attctccaga gagtatagga acttcgacgt cc

52

<210> 28

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 28

ctagttccgg agaagttcct attctgtaga tagtatagga acttcgacgt cc

52

<210> 29

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 29

ctagttccgg agaagttcct attctctgga gagtatagga acttcgacgt cc

52

<210> 30

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 30

ctagttccgg agaagttcct attctcaaga tagtatagga acttcgacgt cc

52

<210> 31

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 31

ctagttccgg agaagttcct attctataga cagtatagga acttcgacgt cc

52

<210> 32

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on mutant FRT sequence.

<400> 32

gaagttccta tactttctac agaataggaa cttc

34

<210> 33

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide based on FLP recognition sequence.

<400> 33

aaattccgga gaagttccta ttctctagaa agtataggaa cttcgacgtc attt

54

<210> 34

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide as polylinker based on recognition sequences of SmaI, EcoRI, ScaI, KpnI and SmaI, in this order.

<400> 34

aaattgaatt cgagctcggt acccggg

27

<210> 35

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide as linker based on sequence encoding BglI
I recognition sequence, two stop codons, and XhoI recognition sequence.

<400> 35

gatcttacta gtaggatc

18

<210> 36

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide as linker based on sequence encoding BglI
I recognition sequence, two stop codons, and XhoI recognition sequence.

<400> 36

tcgagatcct actagtaa

18